Skip to main content

Table 1 Study outcomes and data sources

From: Study protocol of a randomized controlled trial to assess safety of teleconsultation compared with face-to-face consultation: the ECASeT study

Item

Domain definition

Measure and metrics

Data sourcesa

Primary outcome

 Rate of complicationsb of the baseline disease

A secondary disease, an accident, or a negative reaction (including adverse reactions to treatment) occurring during the course of the baseline disease and usually aggravating the illness.

Measure: events, as recorded in the eCRF.

Metrics and aggregation: event rate (i.e., proportion of patients experiencing an event within each arm and the follow-up period).

Investigator-reported in the eCRF

Local EHR.

Secondary outcomes

 Rate of severe complications of the baseline illness

A complication with significant impact on patient’s life and/or that require intervention by a healthcare professional

Measure: events, as recorded in the eCRF.

Metrics and aggregation: event rate (i.e., proportion of patients experiencing an event within each arm and the follow-up period).

Investigator-reported in the eCRF

Local EHR.

 Rate of severe adverse reactions related to the treatment of the baseline condition

An undesired health event related to a drug administered to treat the baseline health condition

Measure: events, as recorded in the eCRF.

Metrics and aggregation: event rate (i.e., proportion of patients experiencing an event within each arm and the follow-up period).

Investigator-reported in the eCRF

 Rate of preventable hospitalizations

Hospitalizations due to illnesses secondary to the chronic diseases that can be managed in the outpatient settingc

Measure: events, as recorded in the eCRF.

Metrics and aggregation: event rate (i.e., proportion of patients experiencing an event within each arm and the follow-up period).

Local EHR

 Non-scheduled medical encounters related to poor control of the baseline disease

The following events will be considered:

• Non-scheduled appointments (phone, videoconference, or face-to-face).

• Visits to primary care services.

• Visits to the emergency room.

• Hospital admissions.

Measure: events, as recorded in the eCRF.

Metrics and aggregation: event rate (i.e., proportion of patients experiencing an event within each arm and the follow-up period).

Investigator-reported in the eCRF

Local EHR

 Pharmaceutical prescriptions

The number of new prescriptions and renewals will be collected, along with the type of pharmaceutical prescription: long-term, acute process, or pro re nata.

Measure: ATC groups prescribed

Metrics and aggregation: difference in number of ATC groups between baseline and last visit; the outcome will be measured as the mean and standard deviation, and median and interquartile range (i.e., 25th and 75th percentiles).

Administrative records.

 Usability

Usability parameters will be collected using two approaches:

• Computer System Usability Questionnaire.

• Technical incidents reported by the investigators.

Measure: Questionnaire score and number of technical incidents.

Metrics and aggregation: score, expressed as the mean and standard deviation, and median and interquartile range (i.e., 25th and 75th percentiles).

Cumulative number of incidents.

Phone call administration by trained interviewers to 10% of the study sample.

Investigator report to the eCRF.

 Satisfaction

Satisfaction survey CSAPG included in the satisfaction survey plan of the Catalan Health System.

Measure: Questionnaire score.

Metrics and aggregation: score, expressed as the mean and standard deviation, and median and interquartile range (i.e., 25th and 75th percentiles).

Phone call administration by trained interviewers to 10% of the study sample.

 Care provision expenditure

Expenses related to each of the interventions.

Measure: cost in euros of the year.

Metrics and aggregation: mean and standard deviation per patient.

Administrative records.

  1. EHR electronic health record
  2. aIn outcomes gathered from more than one data source, discrepancies or inconsistencies between data sources will be addressed by the scientific committee before the closure of the database
  3. bThe severity of complications and adverse events will be recorded using a scale with four categories: (a) MILD: does not limit activity and does not require medical follow-up; (b) MODERATE: mild-to-moderate impact on activity or requires minimal medical intervention or monitoring; (c) SEVERE: significant impact on activity or requires medical care; (d) VERY SEVERE: life-threatening or results in major disability or significant incapacity for the subject
  4. cThe list of conditions considered has been retrieved from ambulatory care sensitive conditions and include ICD-10 categories related to ischemic heart (I20, I240, I248, I249), asthma (J45, J46), COPD (J20, J41, J42, J43, J44, J47), heart failure (I110, I50, J81), seizures (G40, G41, R56, O15), diabetes (E100-E108, E110-E118, E120-E128, E130-E138, E140-E148), hypertension (I10, I119), and iron-deficiency anemia (D501, D508, D509)